Evidence map›Paper›PMID 31661039›Full record

ArticleActa neuropathologica communications2019

Tumors diagnosed as cerebellar glioblastoma comprise distinct molecular entities.

Annekathrin Reinhardt, Damian Stichel, Daniel Schrimpf, Christian Koelsche, Annika K Wefers, Azadeh Ebrahimi, Philipp Sievers, Kristin Huang, M Belén Casalini, Francisco Fernández-Klett and 35 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Acta neuropathologica communications, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 42 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
42citing papers in PubMed, 3 pooled it
4.6field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

42 citing papers in PubMed, 3 syntheses or guidelines pooled it, 62 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Guideline
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. The Spectrum of IDH- and H3-Wildtype High-Grade Glioma Subgroups Occurring across Teenage and Young Adult Patient Populations.Clinical cancer research : an official journal of the American Association for Cancer Research · 2025
    Article
  12. Article
  13. Review
  14. Review
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

45 authors at 20 institutions in 3 countries.

Annekathrin ReinhardtDepartment of Neuropathology, University Hospital Heidelberg, Im Neuenheimer Feld 224, 69120, Heidelberg, Germany.
Damian StichelDepartment of Neuropathology, University Hospital Heidelberg, Im Neuenheimer Feld 224, 69120, Heidelberg, Germany.
Daniel SchrimpfDepartment of Neuropathology, University Hospital Heidelberg, Im Neuenheimer Feld 224, 69120, Heidelberg, Germany.
Christian KoelscheDepartment of Neuropathology, University Hospital Heidelberg, Im Neuenheimer Feld 224, 69120, Heidelberg, Germany.
Annika K WefersDepartment of Neuropathology, University Hospital Heidelberg, Im Neuenheimer Feld 224, 69120, Heidelberg, Germany.
Azadeh EbrahimiDepartment of Neuropathology, University Hospital Heidelberg, Im Neuenheimer Feld 224, 69120, Heidelberg, Germany.
Philipp SieversDepartment of Neuropathology, University Hospital Heidelberg, Im Neuenheimer Feld 224, 69120, Heidelberg, Germany.
Kristin HuangDepartment of Neuropathology, University Hospital Heidelberg, Im Neuenheimer Feld 224, 69120, Heidelberg, Germany.
M Belén CasaliniDepartment of Neuropathology, University Hospital Heidelberg, Im Neuenheimer Feld 224, 69120, Heidelberg, Germany.
Francisco Fernández-KlettDepartment of Neuropathology, University Hospital Heidelberg, Im Neuenheimer Feld 224, 69120, Heidelberg, Germany.
Abigail SuwalaDepartment of Neuropathology, University Hospital Heidelberg, Im Neuenheimer Feld 224, 69120, Heidelberg, Germany.
Michael WellerDepartment of Neurology, University Hospital and University of Zuerich, Zuerich, Switzerland.
Dorothee GramatzkiDepartment of Neurology, University Hospital and University of Zuerich, Zuerich, Switzerland.
Joerg FelsbergInstitute for Neuropathology, Heinrich Heine University Duesseldorf, Duesseldorf, Germany.
Guido ReifenbergerInstitute for Neuropathology, Heinrich Heine University Duesseldorf, Duesseldorf, Germany.
Albert BeckerDepartment of Neuropathology of the University of Bonn, Bonn, Germany.
Volkmar H HansInstitute for Neuropathology of the University of Essen, Essen, Germany.
Marco PrinzInstitute of Neuropathology, Medical Faculty, University of Freiburg, Freiburg, Germany.
Ori StaszewskiInstitute of Neuropathology, Medical Faculty, University of Freiburg, Freiburg, Germany.
Till AckerInstitute of Neuropathology, University of Giessen, Giessen, Germany.
Hildegard DohmenInstitute of Neuropathology, University of Giessen, Giessen, Germany.
Christian HartmannDepartment for Neuropathology, Institute for Pathology, Hannover Medical School, Hannover, Germany.
Werner PaulusInstitute of Neuropathology, University Hospital Muenster, Muenster, Germany.
Katharina HeßInstitute of Neuropathology, University Hospital Muenster, Muenster, Germany.
Benjamin BrokinkelInstitute of Neuropathology, University Hospital Muenster, Muenster, Germany.
Jens SchittenhelmInstitute for Pathology and Neuropathology of the University of Tuebingen, Comprehensive Cancer Center Tuebingen, Tuebingen, Germany.
Rolf BusleiInstitute for Pathology, Sozialstiftung Bamberg, Bamberg, Germany.
Martina DeckertDepartment of Neuropathology, University Hospital of Cologne, Cologne, Germany.
Christian MawrinInstitute for Neuropathology of the University of Magdeburg, Magdeburg, Germany.
Ekkehard HewerInstitute of Pathology, University of Bern, Bern, Switzerland.
Ute PohlDepartment of Cellular Pathology, Queen's Hospital, Romford, UK.
Zane JaunmuktaneDepartment of Molecular Neuroscience, UCL Queen Square Institute of Neurology, Queen Square, London, UK.
Sebastian BrandnerDepartment of Neurodegenerative Disease, UCL Queen Square Institute of Neurology, Queen Square, London, UK.
Andreas UnterbergClinic for Neurosurgery, University Hospital Heidelberg, Heidelberg, Germany.
Daniel HänggiClinic for Neurosurgery, University of Mannheim, Mannheim, Germany.
Michael PlattenDepartment of Neurology, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany.
Stefan M PfisterDivision of Pediatric Neurooncology, German Cancer Research Center (DKFZ), Heidelberg, Germany.
Wolfgang WickNeurology Clinic, University of Heidelberg Medical Center, Heidelberg, Germany.
Christel Herold-MendeDivision of Experimental Neurosurgery, Department of Neurosurgery, Ruprecht-Karls-University Heidelberg, Heidelberg, Germany.
Andrey KorshunovDepartment of Neuropathology, University Hospital Heidelberg, Im Neuenheimer Feld 224, 69120, Heidelberg, Germany.
David E ReussDepartment of Neuropathology, University Hospital Heidelberg, Im Neuenheimer Feld 224, 69120, Heidelberg, Germany.
Felix SahmDepartment of Neuropathology, University Hospital Heidelberg, Im Neuenheimer Feld 224, 69120, Heidelberg, Germany.
David T W JonesHopp Children's Cancer Center Heidelberg (KiTZ), 69120, Heidelberg, Germany.
David CapperDepartment of Neuropathology, University Hospital Heidelberg, Im Neuenheimer Feld 224, 69120, Heidelberg, Germany.
Andreas von DeimlingDepartment of Neuropathology, University Hospital Heidelberg, Im Neuenheimer Feld 224, 69120, Heidelberg, Germany. andreas.vondeimling@med.uni-heidelberg.de.
Heidelberg University · DEUniversity Hospital Heidelberg · DEGerman Cancer Research Center · DEUniversity Hospital Münster · DEHeinrich Heine University Düsseldorf · DEUniversity of Freiburg · DEUniversity of Giessen · DEFriedrich-Alexander-Universität Erlangen-Nürnberg · DEHopp Children's Cancer Center Heidelberg · DEMedizinische Hochschule Hannover · DENational Hospital for Neurology and Neurosurgery · GBQueen's Hospital · GBUniversity College London · GBUniversity Hospital Cologne · DEUniversity Hospital Magdeburg · DEUniversity Medical Centre Mannheim · DEUniversity of Bern · CHUniversity of Bonn · DEUniversity of Mannheim · DEUniversity of Tübingen · DE

Funding

DKFZ HIPO HIPO_036DKTK n.a.Funding program Open Access Publishing by Deutsche Forschungsgemeinschaft, by the Baden-Württemberg Ministry of Science, Research and the Arts and by Ruprecht-Karls-Universität Heidelberg IN-1150438German Cancer Aid 70112371Illumina n.a.National Institute for Health Research BRC399/NS/RB/101410NIHR n.a.UK Department of Health's NIHR Biomedical Research Centre's funding scheme n.a.
6 · The paper itself

Abstract

In this multi-institutional study we compiled a retrospective cohort of 86 posterior fossa tumors having received the diagnosis of cerebellar glioblastoma (cGBM). All tumors were reviewed histologically and subjected to array-based methylation analysis followed by algorithm-based classification into distinct methylation classes (MCs). The single MC containing the largest proportion of 25 tumors diagnosed as cGBM was MC anaplastic astrocytoma with piloid features representing a recently-described molecular tumor entity not yet included in the WHO Classification of Tumours of the Central Nervous System (WHO classification). Twenty-nine tumors molecularly corresponded to either of 6 methylation subclasses subsumed in the MC family GBM IDH wildtype. Further we identified 6 tumors belonging to the MC diffuse midline glioma H3 K27 M mutant and 6 tumors allotted to the MC IDH mutant glioma subclass astrocytoma. Two tumors were classified as MC pilocytic astrocytoma of the posterior fossa, one as MC CNS high grade neuroepithelial tumor with BCOR alteration and one as MC control tissue, inflammatory tumor microenvironment. The methylation profiles of 16 tumors could not clearly be assigned to one distinct MC. In comparison to supratentorial localization, the MC GBM IDH wildtype subclass midline was overrepresented, whereas the MCs GBM IDH wildtype subclass mesenchymal and subclass RTK II were underrepresented in the cerebellum. Based on the integration of molecular and histological findings all tumors received an integrated diagnosis in line with the WHO classification 2016. In conclusion, cGBM does not represent a molecularly uniform tumor entity, but rather comprises different brain tumor entities with diverse prognosis and therapeutic options. Distinction of these molecular tumor classes requires molecular analysis. More than 30% of tumors diagnosed as cGBM belong to the recently described molecular entity of anaplastic astrocytoma with piloid features.

Indexed as

AdolescentAdultAgedAged, 80 and overCerebellar NeoplasmsChildChild, PreschoolCyclin-Dependent Kinase Inhibitor p16ErbB ReceptorsFemaleGlioblastomaHumansInfantInfant, NewbornInfratentorial NeoplasmsMaleCDKN2A protein, humanCyclin-Dependent Kinase Inhibitor p16EGFR protein, humanErbB ReceptorsTelomeraseTERT protein, humanAnaplastic astrocytoma with piloid featuresAnaplastic pilocytic astrocytomaCerebellar glioblastomaCopy number variation loadIntegrated diagnosisMethylation-based classification

Identifiers

PMID31661039
PMCPMC6816155
OpenAlexW2982668939

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.